Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Metrics to compare | AVR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −4.6x | −0.7x | |
PEG Ratio | −0.11 | −0.11 | 0.00 | |
Price/Book | 6.3x | 4.3x | 2.6x | |
Price / LTM Sales | 62.4x | 4.5x | 3.4x | |
Upside (Analyst Target) | 306.0% | 49.5% | 35.5% | |
Fair Value Upside | Unlock | −1.0% | 3.3% | Unlock |